A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis

A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis

Bruton’s tyrosine kinase (BTK) inhibitors are an emerging class of therapeutics in multiple sclerosis (MS). BTK is expressed in B-cells and myeloid cells, key progenitors of which include dendritic cells, microglia and macrophages, integral effectors of MS pathogenesis, along with mast cells, establ...

Full description

Bibliographic Details
Main Authors: Laura Airas, Robert A. Bermel, Tanuja Chitnis, Hans-Peter Hartung, Jin Nakahara, Olaf Stuve, Mitzi J. Williams, Bernd C. Kieseier, Heinz Wiendl
Format: Article
Language:English
Published: SAGE Publishing 2024-04-01
Series:Therapeutic Advances in Neurological Disorders
Online Access:https://doi.org/10.1177/17562864241233041

Similar Items

Similar Items